ADC technology simply explained

daniel-tischler

Daniel Tischler

April 25, 2023

Table of contents

Show

ADC technology is a promising and exciting new approach in cancer treatment, selectively targeting a specific cell surface receptor expressed on cancer cells. With oncology being a main field of application, a number of preclinical tests for treatment of malignancies and solid tumors are currently being conducted.

Their ability to selectively destroy tumor cells makes antibody-drug conjugates highly potent. However, understanding the pharmacokinetics of ADCs is important for optimizing their therapeutic potential.

ADC technology – a definition

By definition, ADC technology is a type of targeted cancer therapy that combines the specificity of mAbs with the cytotoxic effects of chemotherapeutic drugs. ADCs are a common type of bioconjugate designed to selectively bind to cancer cells. This allows them to deliver the small molecule drug – more precisely cytotoxic (anti-cancer) drugs – directly to the tumor cells while minimizing damage to healthy cells.

How do ADC therapeutics work?

ADCs work by connecting a monoclonal antibody with a cytotoxic drug via linker. After having been administered intravenously, they recognize and bind to antigens as target structures on the surface of cancer cells. The toxin is internalized in the cancer cell, where it is then released.

Compared to other types of therapy, ADCs come with less side effects and a more favorable therapeutic index. And because they are also able to act on dormant cells, there is an increasing number of FDA-approved antibody-drug conjugates available, bringing new hope to severely ill patients.

How do ADC therapeutics work?

ADC technology – designing Antibody-Drug Conjugates

ADC technology that aims at improving antitumor activity while minimizing side effects for patients and increasing the therapeutic window. At the same time, ADC manufacturing and ADC development leads to the innovation of new classes of linkers that specifically deliver the maximum cell-killing dose to target cells.

Antibody-drug conjugates are complex molecules that are composed of three main components: 

  • Monoclonal antibody 
  • Cytotoxic drug 
  • Linker

Given the right combination, these three components work together to create a highly site-specific and potent therapeutic agent. Having recognized the potential of such agents, antibody-drug conjugate companies produce approved ADCs that can selectively kill cancer cells while minimizing damage to healthy ones. Such companies can be set up as CDMOs, helping in streamlining processes and production in the pharma industry.

Antibody

Antibody-drug conjugates typically use monoclonal antibodies with a high specificity and affinity for a particular antigen.

MAbs are important for the mechanism of action; they are designed to be highly selective, so they can specifically bind to cancer cells while at the same time sparing healthy cells. Any ADC’s antibody component is generally derived from hybridoma cell lines or by using recombinant DNA technology.

Cytotoxic payload

The term cytotoxic payload refers to a type of payload that is designed to induce cell death or destruction upon internalization. The payload range or drug-to-antibody ratio, DAR in short, can vary. It can be a chemical compound, biological molecule, or other agent that targets specific cells or tissues.

The design of the cytotoxic payload is what makes the ADC a powerful therapeutic tool, and there are several commonly used toxic payloads.

  • DNA binding cytotoxic agents such as topoisomerase inhibitors
  • Tubulin inhibitors such as Maytansinoids

Linkers

Linkers are the component connecting the antibody and the cytotoxic drug. They play a crucial role in determining an ADC’s efficacy and safety. A linker must be stable enough for the drug to remain attached to the antibody in circulation, while it should also be cleavable in the cancer cell to release the cytotoxic drug.

The linker is critical as it must ensure that the drug is released at the optimal rate and in the right location in order to maximize its therapeutic effect while reducing the risk of side effects.

Therapeutic application of ADCs

ADCs have shown promising results in the treatment of lymphoma, leukemia, breast cancer and other solid tumors. They are able to target a variety of antigens expressed on the surface of cancer cells such as CD20 in lymphoma or HER2 in breast cancer.

Examples of antibody-drug conjugates already available on the market include are:

  • Adcetris (brentuximab vedotin) for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma, consisting of an anti-CD30 MAB conjugated to the cytotoxic drug monomethyl auristatin E (MMAE)
  • Kadcyla (ado-trastuzumab emtansine) and Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2-positive breast cancer, both consisting of the anti-HER2 monoclonal antibody trastuzumab conjugated to the cytotoxic drug DM1 (Kadcyla), respectively DXd (Enhertu)

In addition to these approved ADCs, there are many others currently undergoing clinical trials and in clinical development.

Challenges and chances of ADC technology

Compared to traditional chemotherapy, conjugation technology brings a number of advantages, including improved efficacy and reduced toxicity. However, there are also some challenges that need to be addressed, not only in terms of efficacy and safety, but also regarding their handling.

Safe handling plays a particularly important role when it comes to the general handling, transport and storage of ADCs, as they include toxic substances. Automated systems that facilitate closed processing and put an end to the necessity of cleaning are a feasible and safe solution provided by single-use technologies.

In order to ensure the safety of any operators involved in the manufacturing process, a safe fluid management of ADCs is particularly crucial. To ensure safe production and logistics processes, careful and protected handling should be ensured throughout.

The same is true for controlled freezing of ADCs, which is where Single Use Support’s robust shell system for frozen storage and shipping and its plate-based freezing and thawing platforms comes into play. The protective shell comprises an outer sleeve of robust stainless-steel and an adaptive inner layer of 3D foam. The result is a closed system around single-use systems that can contribute to the safe transport and storage of high-value and potentially harmful substances.

Challenges and chances of ADC technology

Navigating 5 Overlooked Challenges in Bioconjugate Manufacturing

This guide for bioconjugate manufacturing with regards to fluid and cold chain management addresses challenges such as: protection against ADC toxicity, accuracy in fluid management, maintaining ADC stability after freeze-thaw cycles, transition from lab to commercialization, and cost considerations of equipment.
daniel-tischler

Daniel Tischler

Director Integrated Solutions

Daniel Tischler is Director Integrated Solutions with experience in sales & business development, product line management, application engineering at Single Use Support.

Proximity to mechatronic systems and to customers were two constants for Daniel Tischler. At Single Use Support he started as a project manager. Later he provided customers technical insights as sales application engineer. Daniel was Head of Product Line Management working on new innovations for customers in the biopharmaceutical industry, before he has started as Director of Commercial Operations.

Daniel has gained 10+ years of expertise in design engineering and project management before he joined Single Use Support.

More from Daniel Tischler

Monoclonal Antibodies

The 3 Most Overlooked Costs in Monoclonal Antibody Production

In the quest for efficient monoclonal antibody manufacturing, it's imperative to shed light on costs that are frequently underestimated. These costs can stem from various sources, including process development, high prices associated with biotherapeutics, and the evolving landscape of production technologies.

daniel-tischler

Daniel Tischler

February 6, 2024

Vaccines

13 vaccine manufacturing companies you need to know

The vaccine market is shaped by numerous companies, from smaller newcomers to international concerns. In this article, we will uncover 13 vaccine manufacturing companies you ought to know.

daniel-tischler

Daniel Tischler

December 4, 2023

Read more about Bioconjugates

Bioconjugates

Transport & Storage of Antibody Drug Conjugates (ADCs)

ADCs can be described as a new rising star among biopharmaceutics. They are able to specifically target and destroy cancer cells very effectively. Their levels of toxicity can vary depending on several factors, including their specific design and the potency of the cytotoxic drug. This is why safe handling in between facilities is such an important issue and must not be taken lightly.

BRMO

Brian Moloney

May 9, 2023

Bioconjugates

FDA approved Antibody Drug Conjugates (ADCs)

ADCs offer new, highly promising approaches in the therapy of various cancer types, and the number of approved ADCs is continuously growing. In this article, we will have a look at ADCs currently approved.

michael-muehlegger

Michael Mühlegger

May 7, 2024

Bioconjugates

Examples of Antibody-drug conjugates

Depending on their constituents, ADCs are extremely variable and can be used for several, very distinct purposes. In this article, we will present you 5 examples of ADCs and their respective characteristics.

BRMO

Brian Moloney

April 25, 2023

Bioconjugates

Bioconjugates: Examples & Applications

Bioconjugates are powerful tools in several areas of life sciences and beyond. In this article, we will have a look at the technology in general as well as at examples of bioconjugates in specific fields.

micheal-eder

Michael Eder

April 26, 2023